Tipelukast clinical trials
Also written MN-001.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2005
How each study uses tipelukast is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2016 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
MediciNova (4)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test tipelukast.
- Dec 2026MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaPhase 2 · MediciNova
Studies
Open first, then newest update. How each study uses tipelukast is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and HypertriglyceridemiaActive, not recruitingPhase 2MediciNovaNCT05464784Written as MN-001How we know
- Safety, Tolerability, and Efficacy of MN-001 (Tipelukast) in Patients With Idiopathic Pulmonary FibrosisCompletedPhase 2MediciNovaNCT02503657Written as MN-001How we know
- Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD SubjectsCompletedPhase 2MediciNovaNCT02681055Written as MN-001How we know
- Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial CystitisCompletedPhase 2MediciNovaNCT00295854Written as MN-001 BIDHow we know
Codes
What other systems call tipelukast · ClinicalTrials.gg INT005225
- UNII (FDA) 08379P260OTIPELUKASTConfirmed FDA, Wikidata
- Wikidata Q27236352tipelukastConfirmed FDA, Wikidata
- NCI Thesaurus C74581TipelukastOne source FDA
- DrugBank DB12435One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 08379P260O | TIPELUKAST | Confirmed FDA, Wikidata |
| Wikidata | Q27236352 | tipelukast | Confirmed FDA, Wikidata |
| NCI Thesaurus | C74581 | Tipelukast | One source FDA |
| DrugBank | DB12435 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.